Navigation Links
Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
Date:7/2/2008

e a possible basis for treatment stratification to LOR-2040 and high dose cytarabine combination.

Favorable disease responses included complete responses in 35% of the 23 patients and significant cytoreduction of leukemic blasts in two others. As a further favourable outcome, these two patients and five of the patients who had complete responses were able to progress to a successful transplant, a desired outcome of successful salvage therapy. Notably, the study population included unfavourable patients with at least one adverse prognostic characteristic.

The clinical study also measured intracellular uptake of LOR-2040 in the bone marrow leukemic cells, and identified significant accumulation of the drug in the bone marrow blast cells and suggested preferential uptake of the drug by CD34+ cells, an important malignant bone marrow cell population.

The authors concluded that LOR-2040 in combination with high dose cytarabine is feasible, is active against its target R2, and "holds promise in younger patients with refractory or relapsed AML". The tolerability profile of this combination regimen was assessed as similar to that expected from high dose cytarabine alone.

"This successful clinical study has provided a detailed supporting rationale for our ongoing development program with LOR-2040 in AML", said Dr Aiping Young, Lorus' President and CEO. "This study supports Lorus' view that a highly specific targeted therapy approach can achieve efficacy with minimal impact on toxicity".

A Phase II program with LOR-2040 in this combination is presently ongoing to extend and confirm these findings in patients with refractory or relapsed AML.

About LOR-2040

LOR-2040 (formerly GTI-2040) is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. Through downregulation of R2, LOR-2040 has demonstrated strong antitumor and antimetastatic act
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 21, 2014 The ... the inorganic refrigerants market in Americas with analysis ... TOC of the Americas Inorganic Refrigerants Market report, ... provided. This also provides a glimpse of the ... is supported by various tables and figures. ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for its Oral Amphotericin B program.  The company ... vitro work involving samples from HIV/AIDS patients ... complete pre clinical studies and regulatory filings to ... trial, utilizing approximately $700,000 of funding and technological ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Abstract , ... with differing surface treatment procedures and carbon content levels , ... , Introduction ... been , made commercially available that offer optimized properties for ...
... , Dr. Karl-Heinz Esser, multiBIND biotec GmbH, ... AppliChem GmbH and, , ... , , , ... gene technology demonstrate,that even small amounts of free DNA molecules,are sufficient to cause ...
... Recommended Cecil Instrumentation: , Cecil Adept HPLC ... Fraction collector , Column heater, ... Researchers need to understand the expression of proteins. ... diseased cells. , Hence the study of proteomics, which ...
Cached Biology Technology:TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 2TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 3New Insights Into DNA Decontamination 2New Insights Into DNA Decontamination 3New Insights Into DNA Decontamination 4New Insights Into DNA Decontamination 5Semi Preparative Purification of Proteins 2
(Date:10/14/2014)... study published in Cancer Research shows SIRT6—a ... colon cancers—can promote the development of skin cancers by ... survival of sun-damaged skin cells. , Previously considered protective, ... called sirtuins that help regulate genomic stability and prevent ... helps repair DNA damage, which can lead to cancer. ...
(Date:10/14/2014)... leading questions is how to produce enough food to ... Food and Agriculture Organization of the United Nations predicts ... 40 years to feed a growing global population, and ... in food production. Plants—grains, cereals, fruits, vegetables, and ... Current research must tap into our knowledge of how ...
(Date:10/14/2014)... – October 14, 2014 – Scientists from The Scripps ... the National Institutes of Health (NIH) to lead an ... hemorrhagic fever disease in Africa. The study aims to ... some patients die, while others survive the inflection. ... the basic mechanism of how Lassa fever virus causes ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... to Research Careers) Program has announced the travel award recipients ... in Los Angeles, CA from June 26-30, 2013. These awards ... scientists from underrepresented groups into the mainstream of the basic ... at the GSA: 19th International C. elegans Meeting. ...
... FASEB MARC (Maximizing Access to Research Careers) Program ... for the Study of Reproduction meeting in Montreal, Canada ... promote the entry of students, postdoctorates and scientists from ... community and to encourage the participation of young scientists ...
... of households could go a long way to reducing greenhouse ... in energy demands at the household level, appears in the ... Saner and colleagues point out that the energy people use ... accounts for more than 70 percent of emissions of carbon ...
Cached Biology News:
... Description: ,Kit containing Dermal Fibroblasts ... supplied as a long-term culture, and is ... of continuous growth from the date supplied, ... ,Source: Dermis, mouse/BalbC, embryonic day 18.5 ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
... a user-friendly statistical software package for scientists ... statistical analysis without being a statistical expert.Just ... and research and SigmaStat suggests the appropriate ... tests underlying assumptions and suggests another test ...
... Service, We deliversoluble protein or No ... yields the best soluble protein results , ... clone submitted , Powerful results on your ... Solubility Optimization Service (SOS) uses proprietary tools ...
Biology Products: